Item 5.02 Election of Director; Departure of Certain Officers; Appointment of
Certain Officers; Compensatory Arrangement of Certain Officers.
On January 16, 2020, the Board of Directors of Q2Earth, Inc. ("Q2Earth" or the
"Company") appointed Douglas R. Baum as a director of Q2Earth, effective
immediately. Mr. Baum currently serves as a consultant to several drug
development companies. From 2011 to January 2017 he served as President and CEO
at Xeris Pharmaceuticals overseeing production of approvals through the FDA and
capital raising.
Other than his appointment to the Q2Earth board during the past 5 years, Mr.
Baum has not served on the board of directors of any company that was required
to file reports pursuant to the Securities Exchange Act of 1934, as amended, or
was a registered investment company under the Investment Company Act of 1940, as
amended. Mr. Baum was granted a 5-year option to purchase 200,000 shares of the
Company's commons stock exercisable at $0.02 per share. The options vest
one-half in 12 months and the balance in 24 months.
The Company issued a Press Release announcing the appointment of Mr. Baum, copy
of which is attached as Exhibit 99.1 and is incorporated by reference
Item 9.01 Financial Statements Pro Forma Financial Information and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release issued by Q2Earth on January 16, 2020.
© Edgar Online, source Glimpses